196 related articles for article (PubMed ID: 24004716)
21. Histone H1 and Chromosomal Protein HMGN2 Regulate Prolactin-induced STAT5 Transcription Factor Recruitment and Function in Breast Cancer Cells.
Schauwecker SM; Kim JJ; Licht JD; Clevenger CV
J Biol Chem; 2017 Feb; 292(6):2237-2254. PubMed ID: 28035005
[TBL] [Abstract][Full Text] [Related]
22. Quantification of PRL/Stat5 signaling with a novel pGL4-CISH reporter.
Fang F; Antico G; Zheng J; Clevenger CV
BMC Biotechnol; 2008 Feb; 8():11. PubMed ID: 18254957
[TBL] [Abstract][Full Text] [Related]
23. Zinc Finger Homeodomain Factor Zfhx3 Is Essential for Mammary Lactogenic Differentiation by Maintaining Prolactin Signaling Activity.
Zhao D; Ma G; Zhang X; He Y; Li M; Han X; Fu L; Dong XY; Nagy T; Zhao Q; Fu L; Dong JT
J Biol Chem; 2016 Jun; 291(24):12809-12820. PubMed ID: 27129249
[TBL] [Abstract][Full Text] [Related]
24. Stat5 activation inhibits prolactin-induced AP-1 activity: distinct prolactin-initiated signals in tumorigenesis dependent on cell context.
Gutzman JH; Rugowski DE; Nikolai SE; Schuler LA
Oncogene; 2007 Sep; 26(43):6341-8. PubMed ID: 17438530
[TBL] [Abstract][Full Text] [Related]
25. Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes.
Peck AR; Witkiewicz AK; Liu C; Klimowicz AC; Stringer GA; Pequignot E; Freydin B; Yang N; Ertel A; Tran TH; Girondo MA; Rosenberg AL; Hooke JA; Kovatich AJ; Shriver CD; Rimm DL; Magliocco AM; Hyslop T; Rui H
Breast Cancer Res; 2012 Oct; 14(5):R130. PubMed ID: 23036105
[TBL] [Abstract][Full Text] [Related]
26. Negative cross talk between NFAT1 and Stat5 signaling in breast cancer.
Zheng J; Fang F; Zeng X; Medler TR; Fiorillo AA; Clevenger CV
Mol Endocrinol; 2011 Dec; 25(12):2054-64. PubMed ID: 21964595
[TBL] [Abstract][Full Text] [Related]
27. Prolactin receptor regulates Stat5 tyrosine phosphorylation and nuclear translocation by two separate pathways.
Ali S; Ali S
J Biol Chem; 1998 Mar; 273(13):7709-16. PubMed ID: 9516478
[TBL] [Abstract][Full Text] [Related]
28. Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.
Goffin V
Pharmacol Ther; 2017 Nov; 179():111-126. PubMed ID: 28549597
[TBL] [Abstract][Full Text] [Related]
29. Prolactin induces SHP-2 association with Stat5, nuclear translocation, and binding to the beta-casein gene promoter in mammary cells.
Chughtai N; Schimchowitsch S; Lebrun JJ; Ali S
J Biol Chem; 2002 Aug; 277(34):31107-14. PubMed ID: 12060651
[TBL] [Abstract][Full Text] [Related]
30. SOCS3 as a tumor suppressor in breast cancer cells, and its regulation by PRL.
Barclay JL; Anderson ST; Waters MJ; Curlewis JD
Int J Cancer; 2009 Apr; 124(8):1756-66. PubMed ID: 19115200
[TBL] [Abstract][Full Text] [Related]
31. Prolactin and ErbB4/HER4 signaling interact via Janus kinase 2 to induce mammary epithelial cell gene expression differentiation.
Muraoka-Cook RS; Sandahl M; Hunter D; Miraglia L; Earp HS
Mol Endocrinol; 2008 Oct; 22(10):2307-21. PubMed ID: 18653779
[TBL] [Abstract][Full Text] [Related]
32. Reciprocal fine-tuning of progesterone and prolactin-regulated gene expression in breast cancer cells.
Holloran SM; Nosirov B; Walter KR; Trinca GM; Lai Z; Jin VX; Hagan CR
Mol Cell Endocrinol; 2020 Jul; 511():110859. PubMed ID: 32407979
[TBL] [Abstract][Full Text] [Related]
33. Dense collagen-I matrices enhance pro-tumorigenic estrogen-prolactin crosstalk in MCF-7 and T47D breast cancer cells.
Barcus CE; Holt EC; Keely PJ; Eliceiri KW; Schuler LA
PLoS One; 2015; 10(1):e0116891. PubMed ID: 25607819
[TBL] [Abstract][Full Text] [Related]
34. Hormone-sensing cells require Wip1 for paracrine stimulation in normal and premalignant mammary epithelium.
Tarulli GA; De Silva D; Ho V; Kunasegaran K; Ghosh K; Tan BC; Bulavin DV; Pietersen AM
Breast Cancer Res; 2013 Jan; 15(1):R10. PubMed ID: 23369183
[TBL] [Abstract][Full Text] [Related]
35. Estrogen negatively regulates epidermal growth factor (EGF)-mediated signal transducer and activator of transcription 5 signaling in human EGF family receptor-overexpressing breast cancer cells.
Boerner JL; Gibson MA; Fox EM; Posner ED; Parsons SJ; Silva CM; Shupnik MA
Mol Endocrinol; 2005 Nov; 19(11):2660-70. PubMed ID: 15976008
[TBL] [Abstract][Full Text] [Related]
36. Prolactin signal transduction to milk protein genes: carboxy-terminal part of the prolactin receptor and its tyrosine phosphorylation are not obligatory for JAK2 and STAT5 activation.
Goupille O; Daniel N; Bignon C; Jolivet G; Djiane J
Mol Cell Endocrinol; 1997 Mar; 127(2):155-69. PubMed ID: 9099911
[TBL] [Abstract][Full Text] [Related]
37. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
Beck MT; Chen NY; Franek KJ; Chen WY
Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
[TBL] [Abstract][Full Text] [Related]
38. Prolactin Signaling Stimulates Invasion via Na(+)/H(+) Exchanger NHE1 in T47D Human Breast Cancer Cells.
Pedraz-Cuesta E; Fredsted J; Jensen HH; Bornebusch A; Nejsum LN; Kragelund BB; Pedersen SF
Mol Endocrinol; 2016 Jul; 30(7):693-708. PubMed ID: 27176613
[TBL] [Abstract][Full Text] [Related]
39. Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer.
Cerliani JP; Guillardoy T; Giulianelli S; Vaque JP; Gutkind JS; Vanzulli SI; Martins R; Zeitlin E; Lamb CA; Lanari C
Cancer Res; 2011 May; 71(10):3720-31. PubMed ID: 21464042
[TBL] [Abstract][Full Text] [Related]
40. Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells.
Wu AM; Dalvi P; Lu X; Yang M; Riddick DS; Matthews J; Clevenger CV; Ross DD; Harper PA; Ito S
Mol Pharmacol; 2013 Feb; 83(2):377-88. PubMed ID: 23150485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
